|
2026
|
G/S
|
Pharmaceutical preparations and substances. |
|
|
G/S
|
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of... |
|
2025
|
G/S
|
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations and substances for t... |
|
|
G/S
|
Pharmaceutical preparations and substances. |
|
|
Invention
|
Jak1 selective inhibitors.
Disclosed herein are compounds of Formula (I),
Disclosed herein are... |
|
|
Invention
|
Chemical compounds.
The present invention relates to azaquinolone compounds of Formula (I), and ... |
|
|
Invention
|
Carboxamide compounds as pkmyt1 inhibitors. Compounds having the structure of Formula (1) and pha... |
|
|
Invention
|
Quinazoline derivatives as gipr antagonists. The present specification relates to compounds of for... |
|
|
Invention
|
Improved cas9 proteins. The disclosure relates to a Cas9 protein comprising a polypeptide sequenc... |
|
|
Invention
|
Combination therapy comprising durvalumab and cisplatin/gemcitabine for use in treating bladder c... |
|
|
Invention
|
Methods, combinations, and uses for the treatment of muscle invasive bladder cancer.
The disclos... |
|
|
Invention
|
Dosage regimen for the treatment of cancer.
The present specification relates to AZD9833 for use... |
|
|
Invention
|
Therapies for wound treatment. The present specification concerns therapeutic approaches for the ... |
|
|
Invention
|
6-aminopurine derivatives useful as polq inhibitors. abb, X, Y, R1, R2, Q1, Q2, and Q3have any of... |
|
|
Invention
|
6-(cyclo)alkoxypurine derivatives useful as polq inhibitors. abb, X, Y, R1, R2, Q1, Q2, and Q3 ha... |
|
|
Invention
|
Methods for treating apol1-mediated kidney disease. The present disclosure provides methods for t... |
|
|
Invention
|
Combination therapy comprising azd0780 and ezetimibe. A method of lowering LDL-C levels, reducing... |
|
|
Invention
|
A spin chamber for an inhaler and an inhaler. A spin chamber (103) for use in an inhaler (200) in... |
|
|
Invention
|
A chimney shuttling mechanism for an inhaler. An inhaler (100, 200, 400) includes a main body (10... |
|
|
Invention
|
An inhaler. An inhaler (100, 200, 300, 400) includes a main body (101) and a drawer (102) to open... |
|
|
Invention
|
Keap1 inhibitors for use in the treatment of bronchiectasis. This specification describes Keap1 i... |
|
|
Invention
|
Conjugates comprising a topoisomerase i inhibitor. The specification relates to conjugates compri... |
|
|
Invention
|
Method of increasing time to second progression and time to first subsequent chemotherapy. The pr... |
|
|
Invention
|
Compositions and methods for delivering a macromolecule to a cell 2. Compounds and methods are pr... |
|
|
Invention
|
Salts and polymorphs of cx3cr1 modulators. The present disclosure provides meglumine salts of CX3... |
|
|
Invention
|
Thio-substituted 1,3,5-triazine cx3cr1 modulators. The present disclosure provides thio-substitut... |
|
|
Invention
|
Small molecule cx3cr1 modulators. 311, pharmaceutical compositions thereof and uses thereof for t... |
|
|
Invention
|
Egfr tkis for use in the treatment of non-small lung cancer.
The specification relates to epider... |
|
|
Invention
|
Treatment of limited-stage small-cell lung cancer with pd-l1 inhibitors. The disclosure relates t... |
|
|
Invention
|
Dose-dependent administration of inhibitor of pnpla3 expression. The present disclosure provides ... |
|
|
Invention
|
Crystalline form of (s)-n-ethyl-3-((9-ethyl-2-(((2r,3s)-2-hydroxypentan-3-yl)amino)-9h-purin-6-yl... |
|
|
Invention
|
Pcsk9 inhibitors and methods of use thereof. A compound with the Formula (I): A-B-C (I) or a phar... |
|
|
Invention
|
Processes and compounds for the preparation of topoisomerase i inhibitor linker-payloads. This sp... |
|
|
Invention
|
Irak4 inhibitors.
The present application relates to chemical compounds of Formula (I), and phar... |
|
2024
|
Invention
|
Arginase inhibitors and methods of use thereof.
Disclosed are compounds of formula (Ia) or a pha... |
|
|
Invention
|
Spin chamber for an inhaler.
A spin chamber for use in an inhaler includes a primary recess to r... |
|
|
Invention
|
Inhaler.
An inhaler includes a main body and a drawer to open out of and close into the main bod... |
|
|
Invention
|
Chimney shuttling mechanism for an inhaler.
An inhaler includes a main body having an inhalation... |
|
2023
|
Invention
|
Anti-ctla antibody compositions and related methods.
The present disclosure provides composition... |
|
|
Invention
|
Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of ... |
|
|
Invention
|
Methods for detecting metabolites using a microfluidic-based ce-ms system.
The present disclosur... |
|
|
Invention
|
Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis.
This disclosure relates... |
|
|
Invention
|
Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-6-morpholinoquinoline-4-carboxami... |
|
|
Invention
|
Combination therapy for treating cancer.
The present provides a method of treating ovarian cance... |
|
|
Invention
|
Methods for unified concentration and buffer exchange.
Provided herein are methods of purifying ... |
|
|
Invention
|
Methods of treating melanoma using tebentafusp and immune checkpoint inhibitors.
The present inv... |
|
|
Invention
|
Solid forms of heterocyclylamides as irak4 inhibitors.
The present specification relates to nove... |
|
|
Invention
|
Predicting albuminuria using machine learning.
An example embodiment may involve obtaining, by a... |
|
|
Invention
|
Combination of albuterol and budesonide for the treatment of asthma.
The present disclosure prov... |
|
|
Invention
|
T cell binding proteins.
The disclosure generally relates to binding proteins that comprise anti... |
|
2022
|
Invention
|
Therapeutic combinations of capivasertib and venetoclax.
Therapeutic combinations of capivaserti... |
|
|
Invention
|
Treatment of lupus.
The disclosure relates to methods and compositions for the treatment of syst... |
